138 results on '"Inserte J"'
Search Results
2. P141Prevention of microtubule disruption with paclitaxel does not protect against infarction in isolated rat hearts
- Author
-
Rodriguez-Sinovas, A, Abad, E, Sanchez, JA, Fernandez-Sanz, C, Inserte, J, Ruiz-Meana, M, and Garcia-Dorado, D
- Published
- 2014
- Full Text
- View/download PDF
3. Iron deficiency is associated with larger infarcts and with adverse remodeling in STEMI patients and reduces myocardial tolerance to ischemia/reperfusion by inhibiting the eNOS/sGC/PKG pathway in mice
- Author
-
Barrabes, J.A, primary, Aluja, D, additional, Castellote, L, additional, Rodriguez, A, additional, Otaegi, I, additional, Pineda, V, additional, Mila, A, additional, Baneras, J, additional, Lidon, R.M, additional, Sambola, A, additional, Rodriguez-Palomares, J, additional, Valente, F, additional, Beneitez, D, additional, Ferreira-Gonzalez, I, additional, and Inserte, J, additional
- Published
- 2020
- Full Text
- View/download PDF
4. Oral pharmacological inhibition of calpains attenuates isoproterenol-induced myocardial hypertrophy and fibrosis
- Author
-
Aluja, D., primary, Inserte, J., additional, Castellano, J., additional, Penela, P., additional, Mayor, F., additional, and Garcia-Dorado, D., additional
- Published
- 2018
- Full Text
- View/download PDF
5. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery
- Author
-
Hausenloy D., Barrabes J., Bøtker H., Davidson S., Di Lisa F., Downey J., Engstrom T., Ferdinandy P., Carbrera-Fuentes H., Heusch G., Ibanez B., Iliodromitis E., Inserte J., Jennings R., Kalia N., Kharbanda R., Lecour S., Marber M., Miura T., Ovize M., Perez-Pinzon M., Piper H., Przyklenk K., Schmidt M., Redington A., Ruiz-Meana M., Vilahur G., Vinten-Johansen J., Yellon D., and Garcia-Dorado D.
- Subjects
Myocardial reperfusion injury ,RISK and SAFE pathway ,Ischaemic conditioning ,Cardioprotection ,Mitochondria - Abstract
© 2016, The Author(s).To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the history of IPC, its evolution to IPost and RIC, myocardial reperfusion injury as a therapeutic target, and future targets and strategies for cardioprotection. This article provides an overview of the major topics discussed at this special meeting and underscores the huge importance and impact, the discovery of IPC has made in the field of cardiovascular research.
- Published
- 2016
6. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery
- Author
-
Hausenloy, D.J. Barrabes, J.A. Bøtker, H.E. Davidson, S.M. Di Lisa, F. Downey, J. Engstrom, T. Ferdinandy, P. Carbrera-Fuentes, H.A. Heusch, G. Ibanez, B. Iliodromitis, E.K. Inserte, J. Jennings, R. Kalia, N. Kharbanda, R. Lecour, S. Marber, M. Miura, T. Ovize, M. Perez-Pinzon, M.A. Piper, H.M. Przyklenk, K. Schmidt, M.R. Redington, A. Ruiz-Meana, M. Vilahur, G. Vinten-Johansen, J. Yellon, D.M. Garcia-Dorado, D.
- Abstract
To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the history of IPC, its evolution to IPost and RIC, myocardial reperfusion injury as a therapeutic target, and future targets and strategies for cardioprotection. This article provides an overview of the major topics discussed at this special meeting and underscores the huge importance and impact, the discovery of IPC has made in the field of cardiovascular research. © 2016, The Author(s).
- Published
- 2016
7. Influence of simulated ischemia on apoptosis induction by oxidative stress in adult cardiomyocytes of rats
- Author
-
INSERTE, J., TAIMOR, G., HOFSTAETTER, B., GARCIA-DORADO, D., and PIPER, H. M.
- Subjects
Ischemia -- Causes of ,Cell death -- Physiological aspects ,Heart cells -- Research ,Oxidation, Physiological -- Analysis ,Hydrogen peroxide -- Research ,Glutathione -- Research ,Biological sciences - Abstract
Inserte, J., G. Taimor, B. Hofstaetter, D. Garcia-Dorado, and H. M. Piper. Influence of simulated ischemia on apoptosis induction by oxidative stress in adult cardiomyocytes of rats. Am. J. Physiol. Heart Circ. Physiol. 278: H94-H99, 2000.--Oxidative stress may cause apoptosis of cardiomyocytes in ischemic-reperfused myocardium. We investigated whether ischemia-reperfusion modifies the susceptibility of cardiomyocyte induction of apoptosis by oxidative stress. Ischemia was simulated by incubating isolated cardiomyocytes from adult rats in an anoxic, glucose-free medium, pH 6.4, for 3 h. Annexin V-fluorescein isothiocyanate/ propidium iodide staining and the detection of DNA laddering were used as apoptotic markers. [H.sub.2][O.sub.2] (7.5 [micro]mol/l) induced apoptosis in 20.1 [+ or -] 1.8% of cells under normoxic conditions but only 14.4 [+ or -] 1.6% (n = 6, P [is less than] 0.05) after ischemia-reoxygenation. This partial protection of ischemic-reoxygenated cells was observed despite a reduction in their cellular glutathione content, from 11.4 [+ or -] 1.9 in normoxic controls to 2.9 [+ or -] 0.8 nmol/mg protein (n = 3, P [is less than] 0.05). Elevation of end-ischemic glutathione contents by pretreatment with 1 mmol/lN-acetylcysteine entirely protected ischemic-reoxygenated cells against induction of apoptosis by [H.sub.2][O.sub.2]. In conclusion, ischemia-reperfusion can protect cardiomyocytes against induction of apoptosis by exogenous oxidative stress. This endogenous protective effect is most clearly demonstrated when control and postischemic cardiomyocytes are compared at similar glutathione levels. simulated ischemia-reoxygenation; hydrogen peroxide; glutathione
- Published
- 2000
8. Calpains in the cardiovascular system
- Author
-
Inserte, J., primary
- Published
- 2012
- Full Text
- View/download PDF
9. Contribution of calpains to myocardial ischaemia/reperfusion injury
- Author
-
Inserte, J., primary, Hernando, V., additional, and Garcia-Dorado, D., additional
- Published
- 2012
- Full Text
- View/download PDF
10. Calcium-mediated cell death during myocardial reperfusion
- Author
-
Garcia-Dorado, D., primary, Ruiz-Meana, M., additional, Inserte, J., additional, Rodriguez-Sinovas, A., additional, and Piper, H. M., additional
- Published
- 2012
- Full Text
- View/download PDF
11. Twenty-five years of preconditioning: are we ready for ischaemia? From coronary occlusion to systems biology and back
- Author
-
Garcia-Dorado, D., primary, Barba, I., additional, and Inserte, J., additional
- Published
- 2011
- Full Text
- View/download PDF
12. Orphan targets for reperfusion injury
- Author
-
Inserte, J., primary, Barrabes, J. A., additional, Hernando, V., additional, and Garcia-Dorado, D., additional
- Published
- 2009
- Full Text
- View/download PDF
13. Delayed recovery of intracellular acidosis during reperfusion prevents calpain activation and determines protection in postconditioned myocardium
- Author
-
Inserte, J., primary, Barba, I., additional, Hernando, V., additional, and Garcia-Dorado, D., additional
- Published
- 2008
- Full Text
- View/download PDF
14. Effect of acidic reperfusion on prolongation of intracellular acidosis and myocardial salvage
- Author
-
Inserte, J., primary, Barba, I., additional, Hernando, V., additional, Abellan, A., additional, Ruiz-Meana, M., additional, Rodriguez-Sinovas, A., additional, and Garcia-Dorado, D., additional
- Published
- 2007
- Full Text
- View/download PDF
15. Triggering of cardiac preconditioning through Na+/K+-ATPase
- Author
-
INSERTE, J, primary
- Published
- 2007
- Full Text
- View/download PDF
16. The end-effectors of preconditioning protection against myocardial cell death secondary to ischemia–reperfusion
- Author
-
GARCIADORADO, D, primary, RODRIGUEZSINOVAS, A, additional, RUIZMEANA, M, additional, INSERTE, J, additional, AGULLO, L, additional, and CABESTRERO, A, additional
- Published
- 2006
- Full Text
- View/download PDF
17. Ischemic preconditioning prevents calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion☆
- Author
-
INSERTE, J, primary, GARCIADORADO, D, additional, HERNANDO, V, additional, BARBA, I, additional, and SOLERSOLER, J, additional
- Published
- 2006
- Full Text
- View/download PDF
18. Membrane association of nitric oxide-sensitive guanylyl cyclase in cardiomyocytes
- Author
-
AGULLO, L, primary, GARCIADORADO, D, additional, ESCALONA, N, additional, RUIZMEANA, M, additional, MIRABET, M, additional, INSERTE, J, additional, and SOLERSOLER, J, additional
- Published
- 2005
- Full Text
- View/download PDF
19. Ischemic preconditioning attenuates calpain-mediated degradation of structural proteins through a protein kinase A-dependent mechanism*1
- Author
-
INSERTE, J, primary
- Published
- 2004
- Full Text
- View/download PDF
20. Left ventricular hypertrophy in rats with biliary cirrhosis
- Author
-
Inserte, J, primary
- Published
- 2003
- Full Text
- View/download PDF
21. Pre-treatment with the Na/H exchange inhibitor cariporide delays cell-to-cell electrical uncoupling during myocardial ischemia
- Author
-
RODRIGUEZSINOVAS, A, primary, GARCIADORADO, D, additional, PADILLA, F, additional, INSERTE, J, additional, BARRABES, J, additional, RUIZMEANA, M, additional, AGULLO, L, additional, and SOLERSOLER, J, additional
- Published
- 2003
- Full Text
- View/download PDF
22. Effect of inhibition of Na+/Ca2+ exchanger at the time of myocardial reperfusion on hypercontracture and cell death
- Author
-
Inserte, J, primary
- Published
- 2002
- Full Text
- View/download PDF
23. Urodilatin limits acute reperfusion injury in the isolated rat heart
- Author
-
Inserte, J, primary
- Published
- 2000
- Full Text
- View/download PDF
24. Cardiac structure and function in experimental intra-hepatic portalhypertension
- Author
-
Perelló, A., primary, Inserte, J., additional, Godoy, A., additional, Puigfel, Y., additional, García-Pagán, J.C., additional, García-Dorado, D., additional, and Bosch, J., additional
- Published
- 2000
- Full Text
- View/download PDF
25. Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes
- Author
-
RUIZMEANA, M, primary, GARCIADORADO, D, additional, JULIA, M, additional, GONZALEZ, M, additional, INSERTE, J, additional, and SOLERSOLER, J, additional
- Published
- 1996
- Full Text
- View/download PDF
26. Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes
- Author
-
Ruiz-Meana, M., primary, Garcia-Dorado, D., additional, Julia, M., additional, Gonzalez, M. A., additional, Inserte, J., additional, and Soler-Soler, J., additional
- Published
- 1996
- Full Text
- View/download PDF
27. Role of the reverse mode of the Na+/Ca2+ exchanger in reoxygenation-induced cardiomyocyte injury.
- Author
-
Schäfer, C, Ladilov, Y, Inserte, J, Schäfer, M, Haffner, S, Garcia-Dorado, D, and Piper, H.M
- Abstract
Objective: We have recently shown that spontaneous Ca2+ oscillations elicit irreversible hypercontracture of cardiomyocytes during reoxygenation. The aim of this study was to investigate whether influx of exterior Ca2+ through the reverse mode of the Na+/Ca2+ exchanger (NCE) contributes to the development of these oscillations and, therefore, to reoxygenation-induced hypercontracture. Methods: Isolated cardiomyocytes and hearts from rats were used as models. Cardiomyocytes were exposed to 60 min simulated ischemia (pHo 6.4) and 10 min reoxygenation (pHo 7.4). During reoxygenation cardiomyocytes were superfused with medium containing 1 mmol/l Ca2+ (control), with nominally Ca2+-free medium or with medium containing 10 μmol/l KB-R 7943 (KB), a selective inhibitor of the reverse mode of the NCE. Results: In reoxygenated cardiomyocytes rapid Ca2+ oscillations occurred which were reduced under Ca2+-free conditions or in presence of KB. Hypercontracture was also significantly reduced under Ca2+-free conditions or in presence of KB. After 30 min of normoxic perfusion isolated rat hearts were subjected to 60 min global ischemia and reperfusion. KB (10 μmol/l) was present during the first 10 min of reperfusion. LVEDP, LVdevP and lactate dehydrogenase (LDH) release were measured. Presence of KB reduced post-ischemic LVEDP and improved left ventricular function (LVdevP). In KB treated hearts the reperfusion induced release of LDH was markedly reduced from 81.1±9.9 (control) to 49.3±8.8 U/60 min/g dry weight. Conclusion: Our study shows that inhibition of the reverse mode of the NCE, during reperfusion only, protects cardiomyocytes and whole hearts against reperfusion injury. [ABSTRACT FROM PUBLISHER]
- Published
- 2001
28. Inhibition by tetanus toxin of sodium-dependent, high-affinity [^3H]5-hydroxytryptamine uptake in rat synaptosomes
- Author
-
Inserte, J., Najib, A., Pelliccioni, P., Gil, C., and Aguilera, J.
- Published
- 1999
- Full Text
- View/download PDF
29. Sodium/Hydrogen Exchanger Inhibition Reduces Myocardial Reperfusion Edema After Normothermic Cardioplegia
- Author
-
Tritto, F.P., Inserte, J., Garcia-Dorado, D., Ruiz-Meana, M., and Soler-Soler, J.
- Abstract
Objective: The hypothesis was that Na^+/H^+ exchange occurring during normothermic cardioplegia contributes to the development of myocardial edema during subsequent reperfusion and impairs functional recovery. Methods: Rat hearts were perfused in a Langendorff apparatus and submitted to 60 minutes of normothermic cardioplegia and 90 minutes of reperfusion. Hearts were allocated to one of four groups (n = 8): inhibition of Na^+/H^+ exchanger with HOE642 throughout the whole experiment (HOE group), only during cardioplegia (HOE-C) or during reperfusion (HOE-R), and a control group. Results: In HOE and HOE-C groups, myocardial water content at the end of reperfusion was lower than in the HOE-R and control groups (526 +/- 19 and 533 +/- 18 ml/100 gm dry tissue vs 632 +/- 25 and 634 +/- 17 ml/100 gm dry tissue, respectively, p = 0.001), left ventricular end-diastolic pressure increased less after reperfusion (46.6 +/- 9.7 and 63.2 +/- 10.0 mm Hg vs 75.1 +/- 4.3 mm Hg and 85.7 +/- 8.9 mm Hg, respectively, p = 0.006), and recovery of left ventricular developed pressure was better (46.7% and 45.8% vs 4.5% and 9.8%, p = 0.048). Relative to the control group, total lactate dehydrogenase release during reperfusion was reduced by 80.2%, 69.3% and 36% in HOE, HOE-C, and HOE-R groups, respectively. Conclusion: Inhibition of the Na^+/H^+ exchange during normothermic cardioplegia reduces myocardial edema and necrosis during subsequent reperfusion, improving functional recovery. Inhibition of Na^+/H^+ exchange during reperfusion only has a much smaller effect. (J Thorac Cardiovasc Surg 1998;115:709-15)
- Published
- 1998
- Full Text
- View/download PDF
30. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery
- Author
-
Dj, Hausenloy, Ja, Barrabes, He, Bøtker, Sm, Davidson, Di Lisa F, Downey J, Engstrom T, Ferdinandy P, Ha, Carbrera-Fuentes, Heusch G, Ibanez B, Ek, Iliodromitis, Inserte J, Jennings R, Kalia N, Rajesh Kharbanda, Lecour S, Marber M, Miura T, and Ovize M
31. RNase1 prevents the damaging interplay between extracellular RNA and tumour necrosis factor-α in cardiac ischaemia/reperfusion injury
- Author
-
Cabrera-Fuentes H., Ruiz-Meana M., Simsekyilmaz S., Kostin S., Inserte J., Saffarzadeh M., Galuska S., Vijayan V., Barba I., Barreto G., Fischer S., Lochnit G., Ilinskaya O., Baumgart-Vogt E., Böning A., Lecour S., Hausenloy D., Liehn E., Garcia-Dorado D., Schlüter K., Preissner K., Cabrera-Fuentes H., Ruiz-Meana M., Simsekyilmaz S., Kostin S., Inserte J., Saffarzadeh M., Galuska S., Vijayan V., Barba I., Barreto G., Fischer S., Lochnit G., Ilinskaya O., Baumgart-Vogt E., Böning A., Lecour S., Hausenloy D., Liehn E., Garcia-Dorado D., Schlüter K., and Preissner K.
- Abstract
© Schattauer 2014 Despite optimal therapy, the morbidity and mortality of patients presenting with an acute myocardial infarction (M1) remain significant, and the initial mechanistic trigger of myocardial “ischaemia/reperfusion (1/R) injury” remains greatly unexplained. Here we show that factors released from the damaged cardiac tissue itself, in particular extracellular RNA (eRNA) and tumour-necrosis-factor α (TNF-α), may dictate 1/R injury. In an experimental in vivo mouse model of myocardial 1/R as well as in the isolated 1/R Langendorff-perfused rat heart, cardiomyocyte death was induced by eRNA and TNF-α. Moreover, TNF-α promoted further eRNA release especially under hypoxia, feeding a vicious cell damaging cycle during 1/R with the massive production of oxygen radicals, mitochondrial obstruction, decrease in antioxidant enzymes and decline of cardiomyocyte functions. The administration of RNase1 significantly decreased myocardial infarction in both experimental models. This regimen allowed the reduction in cytokine release, normalisation of antioxidant enzymes as well as preservation of cardiac tissue. Thus, RNase1 administration provides a novel therapeutic regimen to interfere with the adverse eRNA-TNF-α interplay and significantly reduces or prevents the pathological outcome of ischaemic heart disease.
32. RNase1 prevents the damaging interplay between extracellular RNA and tumour necrosis factor-α in cardiac ischaemia/reperfusion injury
- Author
-
Cabrera-Fuentes H., Ruiz-Meana M., Simsekyilmaz S., Kostin S., Inserte J., Saffarzadeh M., Galuska S., Vijayan V., Barba I., Barreto G., Fischer S., Lochnit G., Ilinskaya O., Baumgart-Vogt E., Böning A., Lecour S., Hausenloy D., Liehn E., Garcia-Dorado D., Schlüter K., Preissner K., Cabrera-Fuentes H., Ruiz-Meana M., Simsekyilmaz S., Kostin S., Inserte J., Saffarzadeh M., Galuska S., Vijayan V., Barba I., Barreto G., Fischer S., Lochnit G., Ilinskaya O., Baumgart-Vogt E., Böning A., Lecour S., Hausenloy D., Liehn E., Garcia-Dorado D., Schlüter K., and Preissner K.
- Abstract
© Schattauer 2014 Despite optimal therapy, the morbidity and mortality of patients presenting with an acute myocardial infarction (M1) remain significant, and the initial mechanistic trigger of myocardial “ischaemia/reperfusion (1/R) injury” remains greatly unexplained. Here we show that factors released from the damaged cardiac tissue itself, in particular extracellular RNA (eRNA) and tumour-necrosis-factor α (TNF-α), may dictate 1/R injury. In an experimental in vivo mouse model of myocardial 1/R as well as in the isolated 1/R Langendorff-perfused rat heart, cardiomyocyte death was induced by eRNA and TNF-α. Moreover, TNF-α promoted further eRNA release especially under hypoxia, feeding a vicious cell damaging cycle during 1/R with the massive production of oxygen radicals, mitochondrial obstruction, decrease in antioxidant enzymes and decline of cardiomyocyte functions. The administration of RNase1 significantly decreased myocardial infarction in both experimental models. This regimen allowed the reduction in cytokine release, normalisation of antioxidant enzymes as well as preservation of cardiac tissue. Thus, RNase1 administration provides a novel therapeutic regimen to interfere with the adverse eRNA-TNF-α interplay and significantly reduces or prevents the pathological outcome of ischaemic heart disease.
33. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery
- Author
-
Hausenloy D., Barrabes J., Bøtker H., Davidson S., Di Lisa F., Downey J., Engstrom T., Ferdinandy P., Carbrera-Fuentes H., Heusch G., Ibanez B., Iliodromitis E., Inserte J., Jennings R., Kalia N., Kharbanda R., Lecour S., Marber M., Miura T., Ovize M., Perez-Pinzon M., Piper H., Przyklenk K., Schmidt M., Redington A., Ruiz-Meana M., Vilahur G., Vinten-Johansen J., Yellon D., Garcia-Dorado D., Hausenloy D., Barrabes J., Bøtker H., Davidson S., Di Lisa F., Downey J., Engstrom T., Ferdinandy P., Carbrera-Fuentes H., Heusch G., Ibanez B., Iliodromitis E., Inserte J., Jennings R., Kalia N., Kharbanda R., Lecour S., Marber M., Miura T., Ovize M., Perez-Pinzon M., Piper H., Przyklenk K., Schmidt M., Redington A., Ruiz-Meana M., Vilahur G., Vinten-Johansen J., Yellon D., and Garcia-Dorado D.
- Abstract
© 2016, The Author(s).To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the history of IPC, its evolution to IPost and RIC, myocardial reperfusion injury as a therapeutic target, and future targets and strategies for cardioprotection. This article provides an overview of the major topics discussed at this special meeting and underscores the huge importance and impact, the discovery of IPC has made in the field of cardiovascular research.
34. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery
- Author
-
Hausenloy D., Barrabes J., Bøtker H., Davidson S., Di Lisa F., Downey J., Engstrom T., Ferdinandy P., Carbrera-Fuentes H., Heusch G., Ibanez B., Iliodromitis E., Inserte J., Jennings R., Kalia N., Kharbanda R., Lecour S., Marber M., Miura T., Ovize M., Perez-Pinzon M., Piper H., Przyklenk K., Schmidt M., Redington A., Ruiz-Meana M., Vilahur G., Vinten-Johansen J., Yellon D., Garcia-Dorado D., Hausenloy D., Barrabes J., Bøtker H., Davidson S., Di Lisa F., Downey J., Engstrom T., Ferdinandy P., Carbrera-Fuentes H., Heusch G., Ibanez B., Iliodromitis E., Inserte J., Jennings R., Kalia N., Kharbanda R., Lecour S., Marber M., Miura T., Ovize M., Perez-Pinzon M., Piper H., Przyklenk K., Schmidt M., Redington A., Ruiz-Meana M., Vilahur G., Vinten-Johansen J., Yellon D., and Garcia-Dorado D.
- Abstract
© 2016, The Author(s).To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the history of IPC, its evolution to IPost and RIC, myocardial reperfusion injury as a therapeutic target, and future targets and strategies for cardioprotection. This article provides an overview of the major topics discussed at this special meeting and underscores the huge importance and impact, the discovery of IPC has made in the field of cardiovascular research.
35. P141 Prevention of microtubule disruption with paclitaxel does not protect against infarction in isolated rat hearts.
- Author
-
Rodriguez-Sinovas, A, Abad, E, Sanchez, JA, Fernandez-Sanz, C, Inserte, J, Ruiz-Meana, M, and Garcia-Dorado, D
- Subjects
MICROTUBULES ,PACLITAXEL ,MYOCARDIAL infarction ,EUKARYOTES ,CYTOSKELETON ,LABORATORY rats - Abstract
Background: Microtubules are highly dynamic polymers present in eukaryote cells that are essential components of cell cytoskeleton. They play an important role in intracellular transport, in maintaining organelle organization and function, and in transmitting mechanical forces within the myocardium. However, this intracellular network becomes disrupted during myocardial ischemia/reperfusion, and it has been proposed that microtubule disruption is an early sign of irreversible ischemic injury, and that prevention of microtubule disruption during ischemia-reperfusion could be beneficial. In this study we aimed to assess the effects of prevention of microtubule disruption with paclitaxel on ischemia/reperfusion injury in both isolated rat cardiomyocytes and isolated, Langendorff-perfused, rat hearts.Methods and results: Isolated rat cardiomyocytes were submitted to normoxia (1h), or to 50 min of anoxia (pH 6.4, 0% O2, 37° C) and 15 min reoxygenation, without or with treatment during anoxia with the microtubule stabilizer paclitaxel (10 μM) or the inhibitor of microtubule polymerization colchicine (5 μM). The condition of microtubule network was assessed by immunofluorescence detection of α-tubulin. Anoxia/reoxygenation leads to disruption of the microtubule network before the onset of ischemic contracture (650±21 vs. 328±11 arbitrary units of fluorescence (auf), p≤0.05). Paclitaxel attenuated both microtubule disruption (377±15 auf, p≤0.05 vs. anoxia/reoxygenation) and the incidence of hypercontracture (31±7 % vs. 56±8 % in anoxia/reoxygenation, p≤0.05) induced by anoxia/reoxygenation, whereas treatment with colchicine mimicked the effects of anoxia/reoxygenation (fluorescence: 188±16 auf, p≤0.01 vs. anoxia/reoxygenation; hypercontracture: 65±7 %). In isolated rat hearts under normoxic conditions, paclitaxel induced a concentration-dependent increase in perfusion pressure and a decrease in heart rate and left ventricular developed pressure. Despite protection against cell hypercontracture, paclitaxel pretreatment did not modify infarct size (60.37±2.27 % in control hearts vs. 58.75±10.25, 55.44±10.32 and 50.06±10.14 % in hearts pretreated with 10-6, 3 10-6 and 10-5 M, of paclitaxel respectively), LDH release or functional recovery after 60 min of global ischemia and reperfusion in isolated rat hearts.Conclusions: Microtubule stabilization with paclitaxel reduces hypercontracture in isolated rat cardiomyocytes but does not protect against infarction in isolated rat hearts. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
36. Spontaneous reperfusion enhances succinate concentration in peripheral blood from stemi patients but its levels does not correlate with myocardial infarct size or area at risk
- Author
-
Marta Consegal, Ignasi Barba, Bruno García del Blanco, Imanol Otaegui, José F. Rodríguez-Palomares, Gerard Martí, Bernat Serra, Neus Bellera, Manuel Ojeda-Ramos, Filipa Valente, Maria Ángeles Carmona, Elisabet Miró-Casas, Antonia Sambola, Rosa María Lidón, Jordi Bañeras, José Antonio Barrabés, Cristina Rodríguez, Begoña Benito, Marisol Ruiz-Meana, Javier Inserte, Ignacio Ferreira-González, Antonio Rodríguez-Sinovas, Institut Català de la Salut, [Consegal M, Benito B, Ruiz-Meana M, Inserte J, Rodríguez-Sinovas A] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. [Barba I] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. Faculty of Medicine, University of Vic - Central University of Catalonia (UVicUCC), Vic, Spain. [García Del Blanco B, Otaegui I, Rodríguez-Palomares JF, Martí G, Serra B, Bellera N, Ojeda-Ramos M, Valente F, Carmona MÁ, Miró-Casas E, Sambola A, Lidón RM, Bañeras J, Barrabés JA] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. [Ferreira-González I] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Epidemiología y Salud Pública, CIBERESP, Instituto de Salud Carlos III, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Surgical Procedures, Operative::Cardiovascular Surgical Procedures::Reperfusion [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Infart de miocardi ,Multidisciplinary ,Reperfusió (Fisiologia) ,compuestos orgánicos::ácidos carboxílicos::ácidos acíclicos::ácidos dicarboxílicos::succinatos::ácido succínico [COMPUESTOS QUÍMICOS Y DROGAS] ,Organic Chemicals::Carboxylic Acids::Acids, Acyclic::Dicarboxylic Acids::Succinates::Succinic Acid [CHEMICALS AND DRUGS] ,intervenciones quirúrgicas::procedimientos quirúrgicos cardiovasculares::reperfusión [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio [ENFERMEDADES] ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction [DISEASES] - Abstract
Cardiovascular biology; Diagnostic markers; Prognostic markers Biología cardiovascular; Marcadores de diagnóstico; Marcadores pronósticos Biologia cardiovascular; Marcadors diagnòstics; Marcadors pronòstics Succinate is enhanced during initial reperfusion in blood from the coronary sinus in ST-segment elevation myocardial infarction (STEMI) patients and in pigs submitted to transient coronary occlusion. Succinate levels might have a prognostic value, as they may correlate with edema volume or myocardial infarct size. However, blood from the coronary sinus is not routinely obtained in the CathLab. As succinate might be also increased in peripheral blood, we aimed to investigate whether peripheral plasma concentrations of succinate and other metabolites obtained during coronary revascularization correlate with edema volume or infarct size in STEMI patients. Plasma samples were obtained from peripheral blood within the first 10 min of revascularization in 102 STEMI patients included in the COMBAT-MI trial (initial TIMI 1) and from 9 additional patients with restituted coronary blood flow (TIMI 2). Metabolite concentrations were analyzed by 1H-NMR. Succinate concentration averaged 0.069 ± 0.0073 mmol/L in patients with TIMI flow ≤ 1 and was significantly increased in those with TIMI 2 at admission (0.141 ± 0.058 mmol/L, p
- Published
- 2023
- Full Text
- View/download PDF
37. Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy
- Author
-
David Aluja, Sara Delgado-Tomás, Marisol Ruiz-Meana, José A. Barrabés, Javier Inserte, Institut Català de la Salut, [Aluja D, Delgado-Tomás S] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ruiz-Meana M, Barrabés JA, Inserte J] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Heart Failure ,Cardiovascular Diseases::Heart Diseases::Heart Failure [DISEASES] ,Calpain ,Organic Chemistry ,Calcium-Binding Proteins ,Enzims - Ús terapèutic ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Cardiomegaly ,General Medicine ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,enfermedades cardiovasculares::enfermedades cardíacas::insuficiencia cardíaca [ENFERMEDADES] ,Catalysis ,Computer Science Applications ,Inorganic Chemistry ,Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Cysteine Proteases::Cysteine Endopeptidases::Calpain [CHEMICALS AND DRUGS] ,enzimas y coenzimas::enzimas::hidrolasas::péptido hidrolasas::cisteína proteasas::cisteína endopeptidasas::calpaína [COMPUESTOS QUÍMICOS Y DROGAS] ,Animals ,Physical and Theoretical Chemistry ,Insuficiència renal aguda - Tractament ,Molecular Biology ,Spectroscopy - Abstract
Calpain; Calpastatin; Myocardial hypertrophy Calpaína; Calpastatina; Hipertrofia miocárdica Calpaïna; Calpastatina; Hipertròfia miocàrdica Despite advances in its treatment, heart failure remains a major cause of morbidity and mortality, evidencing an urgent need for novel mechanism-based targets and strategies. Myocardial hypertrophy, caused by a wide variety of chronic stress stimuli, represents an independent risk factor for the development of heart failure, and its prevention constitutes a clinical objective. Recent studies performed in preclinical animal models support the contribution of the Ca2+-dependent cysteine proteases calpains in regulating the hypertrophic process and highlight the feasibility of their long-term inhibition as a pharmacological strategy. In this review, we discuss the existing evidence implicating calpains in the development of cardiac hypertrophy, as well as the latest advances in unraveling the underlying mechanisms. Finally, we provide an updated overview of calpain inhibitors that have been explored in preclinical models of cardiac hypertrophy and the progress made in developing new compounds that may serve for testing the efficacy of calpain inhibition in the treatment of pathological cardiac hypertrophy. This study was funded by the Instituto de Salud Carlos III of the Spanish Ministry of Health FIS-PI20/01681) and the research network CIBERCV (CB16/11/00479).
- Published
- 2022
38. Defective dimerization of FoF1‐ATP synthase secondary to glycation favors mitochondrial energy deficiency in cardiomyocytes during aging
- Author
-
Diana Bou‐Teen, Celia Fernandez‐Sanz, Elisabet Miro‐Casas, Zuzana Nichtova, Elena Bonzon‐Kulichenko, Kelly Casós, Javier Inserte, Antonio Rodriguez‐Sinovas, Begoña Benito, Shey‐Shing Sheu, Jesús Vázquez, Ignacio Ferreira‐González, Marisol Ruiz‐Meana, Instituto de Salud Carlos III, Ministerio de Salud (España), Sociedad Española de Cardiología, Institut Català de la Salut, [Bou-Teen D, Miro-Casas E, Casós K, Inserte J, Rodriguez-Sinovas A, Benito B, Ruiz-Meana M] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Fernandez-Sanz C, Sheu SS] Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, USA. [Nichtova Z] MitoCare Center for Mitochondrial Imaging Research and Diagnostics, Department of Pathology, Anatomy & Cell Biol., Thomas Jefferson University, Philadelphia, USA. [Bonzon-Kulichenko E, Vázquez J] Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain. Cardiovascular Proteomics Laboratory, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain. [Ferreira-González I] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Glycation End Products, Advanced ,Aging ,Mitochondrial Permeability Transition Pore ,Other subheadings::Other subheadings::/metabolism [Other subheadings] ,Cell Biology ,Mitochondrial Proton-Translocating ATPases ,Mitochondria, Heart ,Mice ,Adenosine Triphosphate ,Animals ,Myocytes, Cardiac ,Calcium ,Mitocondris - Malalties ,Cèl·lules - Envelliment ,células::estructuras celulares::espacio intracelular::citoplasma::estructuras citoplasmáticas::orgánulos::mitocondrias::mitocondrias musculares::mitocondrias cardíacas [ANATOMÍA] ,Dimerization ,Cells::Cellular Structures::Intracellular Space::Cytoplasm::Cytoplasmic Structures::Organelles::Mitochondria::Mitochondria, Muscle::Mitochondria, Heart [ANATOMY] ,Otros calificadores::Otros calificadores::/metabolismo [Otros calificadores] - Abstract
Aging; Dicarbonyl stress; Mitochondria Envelliment; Estrès dicarbonílic; Mitocondris Envejecimiento; Estrés dicarbonílico; Mitocondrias Aged cardiomyocytes develop a mismatch between energy demand and supply, the severity of which determines the onset of heart failure, and become prone to undergo cell death. The FoF1-ATP synthase is the molecular machine that provides >90% of the ATP consumed by healthy cardiomyocytes and is proposed to form the mitochondrial permeability transition pore (mPTP), an energy-dissipating channel involved in cell death. We investigated whether aging alters FoF1-ATP synthase self-assembly, a fundamental biological process involved in mitochondrial cristae morphology and energy efficiency, and the functional consequences this may have. Purified heart mitochondria and cardiomyocytes from aging mice displayed an impaired dimerization of FoF1-ATP synthase (blue native and proximity ligation assay), associated with abnormal mitochondrial cristae tip curvature (TEM). Defective dimerization did not modify the in vitro hydrolase activity of FoF1-ATP synthase but reduced the efficiency of oxidative phosphorylation in intact mitochondria (in which membrane architecture plays a fundamental role) and increased cardiomyocytes’ susceptibility to undergo energy collapse by mPTP. High throughput proteomics and fluorescence immunolabeling identified glycation of 5 subunits of FoF1-ATP synthase as the causative mechanism of the altered dimerization. In vitro induction of FoF1-ATP synthase glycation in H9c2 myoblasts recapitulated the age-related defective FoF1-ATP synthase assembly, reduced the relative contribution of oxidative phosphorylation to cell energy metabolism, and increased mPTP susceptibility. These results identify altered dimerization of FoF1-ATP synthase secondary to enzyme glycation as a novel pathophysiological mechanism involved in mitochondrial cristae remodeling, energy deficiency, and increased vulnerability of cardiomyocytes to undergo mitochondrial failure during aging. This work was supported by the Instituto de Salud Carlos III of the Spanish Ministry of Health (FIS-PI19-01196) and a grant from the Sociedad Española de Cardiología (SEC/FEC-INV-BAS 217003)
- Published
- 2022
- Full Text
- View/download PDF
39. Citric Acid Cycle Metabolites Predict Infarct Size in Pigs Submitted to Transient Coronary Artery Occlusion and Treated with Succinate Dehydrogenase Inhibitors or Remote Ischemic Perconditioning
- Author
-
Begoña Benito, Marisol Ruiz-Meana, Javier Inserte, Norberto Núñez, Marta Consegal, Ignacio Ferreira-González, Antonio Rodríguez-Sinovas, Ignasi Barba, Institut Català de la Salut, [Consegal M, Benito B, Ruiz-Meana M, Inserte J, Rodríguez-Sinovas A] Grup de Recerca en Malalties Cardiovasculars, Servei de Cardiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain. [Núñez N] Unitat d'Alta Tecnologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Barba I] Grup de Recerca en Malalties Cardiovasculars, Servei de Cardiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain. Faculty of Medicine, University of Vic-Central University of Catalonia (UVicUCC), Can Baumann. Ctra. de Roda, 70, 08500 Vic, Spain. [Ferreira-González I] Grup de Recerca en Malalties Cardiovasculars, Servei de Cardiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
0301 basic medicine ,Swine ,Endogeny ,030204 cardiovascular system & hematology ,Pharmacology ,ischemia-reperfusion ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction [DISEASES] ,chemistry.chemical_compound ,0302 clinical medicine ,hemic and lymphatic diseases ,Dicarboxylic Acids ,Myocardial infarction ,Biology (General) ,Enzyme Inhibitors ,Ischemic Preconditioning ,Spectroscopy ,remote ischemic conditioning ,biology ,Àcid cítric - Metabolisme ,Chemistry ,Succinate dehydrogenase ,Ischemia-reperfusion ,metabolismo::metabolismo energético::metabolismo::ciclo del ácido cítrico [FENÓMENOS Y PROCESOS] ,Remote ischemic conditioning ,Heart ,General Medicine ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio [ENFERMEDADES] ,Computer Science Applications ,Malonate ,myocardial infarction ,Other subheadings::Other subheadings::/administration & dosage [Other subheadings] ,sustancias macromoleculares::complejos multiproteicos::complejos multienzimáticos::succinato citocromo c oxidorreductasa::complejo II de transporte de electrones::succinato deshidrogenasa [COMPUESTOS QUÍMICOS Y DROGAS] ,QH301-705.5 ,Sodium ,Citric Acid Cycle ,chemistry.chemical_element ,Catalysis ,Great cardiac vein ,Article ,Inorganic Chemistry ,03 medical and health sciences ,Metabolism::Energy Metabolism::Metabolism::Citric Acid Cycle [PHENOMENA AND PROCESSES] ,medicine ,Animals ,Physical and Theoretical Chemistry ,Molecular Biology ,QD1-999 ,Macromolecular Substances::Multiprotein Complexes::Multienzyme Complexes::Succinate Cytochrome c Oxidoreductase::Electron Transport Complex II::Succinate Dehydrogenase [CHEMICALS AND DRUGS] ,Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores] ,Myocardium ,Organic Chemistry ,medicine.disease ,succinate dehydrogenase ,malonate ,Citric acid cycle ,Infart de miocardi ,030104 developmental biology ,Coronary Occlusion ,Inhibidors enzimàtics ,Coronary occlusion ,biology.protein ,Biomarkers - Abstract
Succinate dehydrogenase (SDH) inhibition with malonate during reperfusion reduced myocardial infarction in animals, whereas its endogenous substrate, succinate, is detected in plasma from STEMI patients. We investigated whether protection by SDH inhibition is additive to that of remote ischemic perconditioning (RIC) in pigs submitted to transient coronary artery occlusion, and whether protective maneuvers influence plasma levels of citric acid cycle metabolites. Forty pigs were submitted to 40 min coronary occlusion and reperfusion, and allocated to four groups (controls, sodium malonate 10 mmol/L, RIC, and malonate + RIC). Plasma was obtained from femoral and great cardiac veins and analyzed by LC-MS/MS. Malonate, RIC, and malonate + RIC reduced infarct size (24.67 ± 5.98, 25.29 ± 3.92 and 29.83 ± 4.62% vs. 46.47 ± 4.49% in controls, p <, 0.05), but no additive effects were detected. Enhanced concentrations of succinate, fumarate, malate and citrate were observed in controls during initial reperfusion in the great cardiac vein, and most were reduced by cardioprotective maneuvers. Concentrations of succinate, fumarate, and malate significantly correlated with infarct size. In conclusion, despite the combination of SDH inhibition during reperfusion and RIC did not result in additive protection, plasma concentrations of selected citric acid cycle metabolites are attenuated by protective maneuvers, correlate with irreversible injury, and might become a prognosis tool in STEMI patients.
- Published
- 2021
40. Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion
- Author
-
[Penela P, Mayor Jr F] Departamento de Biología Molecular, Centro de Biología Molecular 'Severo Ochoa' (UAM-CSIC), Madrid, Spain. Instituto de Investigación Sanitaria La Princesa, Madrid, Spain. CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Inserte J, Rodriguez-Sinovas A, Garcia-Dorado D] CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Ramos P] Departamento de Biología Molecular, Centro de Biología Molecular 'Severo Ochoa' (UAM-CSIC), Madrid, Spain and Hospital Universitari Vall d'Hebron
- Subjects
Cardiovascular Diseases::Heart Diseases::Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Cardiovascular Diseases::Cardiovascular Diseases::Myocardial Reperfusion Injury [DISEASES] ,Proteïna quinasa CK2 ,Técnicas de Investigación::Modelos Animales::Técnicas de Investigación::Modelos Animales de Enfermedad [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,metabolism ,Reperfusió miocardíaca ,Models animals en la investigació ,Investigative Techniques::Models, Animal::Investigative Techniques::Disease Models, Animal [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,enfermedades cardiovasculares::enfermedades cardíacas::enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::enfermedades cardiovasculares::enfermedades cardiovasculares::daño por reperfusión miocárdica [ENFERMEDADES] ,metabolismo ,Amino Acids, Peptides, and Proteins::Amino Acids, Peptides, and Proteins::Proteins::Intracellular Signaling Peptides and Proteins::G-Protein-Coupled Receptor Kinases::beta-Adrenergic Receptor Kinases::G-Protein-Coupled Receptor Kinase 2 [CHEMICALS AND DRUGS] ,Aminoácidos, Péptidos y Proteínas::Péptidos::Péptidos y Proteínas de Señalización Intracelular::Quinasas de Receptores Acoplados a Proteína-G::Quinasas de Receptores Adrenérgicos beta::Aminoácidos, Péptidos y Proteínas::Quinasa 2 del Receptor Acoplado a Proteína-G [COMPUESTOS QUÍMICOS Y DROGAS] - Published
- 2021
41. Cardiac fibroblasts display endurance to ischemia, high ROS control and elevated respiration regulated by the JAK2/STAT pathway
- Author
-
Marta Llovera, Marisol Ruiz-Meana, Andrea Irazoki, Carlos Lana, Javier Inserte, Manuel Portero-Otin, Juan G. Valero, Aida Beà, Guillermo López-Lluch, Antonio Zorzano, Daniel Sanchis, Patricia Pérez-Galán, Ministerio de Economía y Competitividad (España), Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Fundació La Marató de TV3, Diputació de Lleida, Generalitat de Catalunya, Instituto de Salud Carlos III, Centres de Recerca de Catalunya, Institut Català de la Salut, [Beà A, Lana C] Cell Signaling & Apoptosis Group, Institut de Recerca Biomedica de Lleida (IRBLleida), Universitat de Lleida, Spain. [Valero JG] Department of Hematology-Oncology, Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Centro de Investigacion Biomédica en Red-Oncología (CIBERONC), Barcelona, Spain. [Irazoki A] Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Universitat de Barcelona, Spain. [López-Lluch G] Andalusian Center of Developmental Biology, Pablo de Olavide University, Sevilla, Spain. Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Sevilla, Spain. [Portero-Otín M] Department of Experimental Medicine, IRBLleida, University of Lleida, Lleida, Spain. [Inserte J, Ruiz-Meana M] Laboratori de Cardiologia Experimental, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Spain. Centro de Investigación Biomédica en Red-CV (CIBER-CV), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
STAT3 Transcription Factor ,Cellular respiration ,Survival ,Cardiac fibrosis ,Sistema cardiovascular - Malalties ,Cardiac fibroblast ,Biochemistry ,Antioxidants ,Ischemia ,medicine ,Animals ,STAT3 ,Molecular Biology ,STAT5 ,enfermedades cardiovasculares [ENFERMEDADES] ,biology ,Cardiovascular Diseases [DISEASES] ,Chemistry ,Respiration ,JAK-STAT signaling pathway ,ROS ,Cell Biology ,Fibroblasts ,Janus Kinase 2 ,medicine.disease ,JAK/STAT ,Cell biology ,Rats ,Proto-Oncogene Proteins c-bcl-2 ,biology.protein ,STAT protein ,Signal transduction ,Janus kinase ,Reactive Oxygen Species ,Signal Transduction - Abstract
Cardiovascular diseases are the leading cause of death globally and more than four out of five cases are due to ischemic events. Cardiac fibroblasts (CF) contribute to normal heart development and function, and produce the post-ischemic scar. Here, we characterize the biochemical and functional aspects related to CF endurance to ischemia-like conditions. Expression data mining showed that cultured human CF (HCF) express more BCL2 than pulmonary and dermal fibroblasts. In addition, gene set enrichment analysis showed overrepresentation of genes involved in the response to hypoxia and oxidative stress, respiration and Janus kinase (JAK)/Signal transducer and Activator of Transcription (STAT) signaling pathways in HCF. BCL2 sustained survival and proliferation of cultured rat CF, which also had higher respiration capacity and reactive oxygen species (ROS) production than pulmonary and dermal fibroblasts. This was associated with higher expression of the electron transport chain (ETC) and antioxidant enzymes. CF had high phosphorylation of JAK2 and its effectors STAT3 and STAT5, and their inhibition reduced viability and respiration, impaired ROS control and reduced the expression of BCL2, ETC complexes and antioxidant enzymes. Together, our results identify molecular and biochemical mechanisms conferring survival advantage to experimental ischemia in CF and show their control by the JAK2/STAT signaling pathway. The presented data point to potential targets for the regulation of cardiac fibrosis and also open the possibility of a general mechanism by which somatic cells required to acutely respond to ischemia are constitutively adapted to survive it., This research was funded by Ministerio de Ciencia e Innovación (MICINN), Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to DS; Fundació La Marató TV3, grant number 20153810 to D.S; A.B. holds a contract from Fundació La Marató TV3 and IRBLleida/Diputació de Lleida; Generalitat de Catalunya, (AGAUR) grant number 2017SGR996 to DS; PP-G Laboratory support was obtained through research grants from MICINN (SAF2017/88275R) and CIBERONC (CB16/12/00334); JI and MR-M Laboratory support was obtained from Instituto de Salud Carlos III (ISCIII-FIS) grant PI19-01196; AZ Laboratory support was obtained through research grants from MICINN (PID2019-106209RB-I00), and the Generalitat de Catalunya, (AGAUR) grant number 2017SGR1015. AZ is a recipient of an ICREA ‘Academia’ Award (Generalitat de Catalunya). We gratefully acknowledge institutional funding from the MINECO through the Centres of Excellence Severo Ochoa Award, and from the CERCA Programme of the Generalitat de Catalunya.
- Published
- 2021
42. Implications of Iron Deficiency in STEMI Patients and in a Murine Model of Myocardial Infarction
- Author
-
Jordi Bañeras, Filipa Valente, Ignacio Ferreira-González, Imanol Otaegui, Ana Sánchez, Laura Castellote, Begoña Benito, Agnès Rafecas, José A. Barrabés, Javier Inserte, José Rodríguez-Palomares, Antonio Rodríguez-Sinovas, Victor Pineda, Elisabet Miró-Casas, Sara Delgado-Tomas, David Beneítez, Rosa-Maria Lidón, Irene Buera, Laia Milà, Antonia Sambola, David Aluja, Marisol Ruiz-Meana, Institut Català de la Salut, [Inserte J, Barrabés JA, Aluja D, Otaegui I, Bañeras J, Sánchez A, Rodríguez-Palomares JF, Miró-Casas E, Milà L, Lidón RM, Sambola A, Valente F, Rafecas A, Ruiz-Meana M, Rodríguez-Sinovas A, Benito B, Buera I, Delgado-Tomás S, Ferreira-González I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Castellote L] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Beneítez D] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
medicine.medical_treatment ,myocardial reperfusion ,intervenciones quirúrgicas::intervenciones quirúrgicas::procedimientos quirúrgicos mínimamente invasivos::procedimientos endovasculares::cirugía coronaria percutánea [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores] ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction [DISEASES] ,iron deficiency ,CMR, cardiac magnetic resonance ,enfermedades hematológicas y linfáticas::enfermedades hematológicas::anemia::anemia hipocrómica::anemia ferropénica [ENFERMEDADES] ,ID, iron deficiency ,Myocardial infarction ,sGC, soluble guanylyl cyclase ,Malalties coronàries - Cirurgia - Complicacions ,medicine.diagnostic_test ,CK-MB, creatine kinase-myocardial band ,eNOS, endothelial nitric oxide synthase ,Iron deficiency ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio [ENFERMEDADES] ,Surgical Procedures, Operative::Surgical Procedures, Operative::Minimally Invasive Surgical Procedures::Endovascular Procedures::Percutaneous Coronary Intervention [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Sgc, soluble guanylyl cyclase ,Cardiology ,cardiovascular system ,iNOS, inducible nitric oxide synthase ,Infart de miocardi - Imatgeria ,Cardiology and Cardiovascular Medicine ,STEMI, ST-segment elevation acute myocardial infarction ,soluble guanylate cyclase ,medicine.medical_specialty ,Ischemia ,acute myocardial infarction ,Acute myocardial infarction ,MVO, microvascular obstruction ,Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia::Anemia, Hypochromic::Anemia, Iron-Deficiency [DISEASES] ,Myocardial reperfusion ,Enos, endothelial nitric oxide synthase ,Cardiac magnetic resonance imaging ,Clinical Research ,Internal medicine ,STIR, short tau inversion recovery ,Other subheadings::Other subheadings::/adverse effects [Other subheadings] ,medicine ,Soluble guanylate cyclase ,HSP90, heat-shock protein 90 ,cardiovascular diseases ,Ventricular remodeling ,LV, left ventricular ,endothelial nitric oxide synthase ,Dèficit de ferro ,business.industry ,Percutaneous coronary intervention ,medicine.disease ,Coronary occlusion ,Inos, inducible nitric oxide synthase ,PKG, protein kinase G ,Endothelial nitric oxide synthase ,business ,cGMP-dependent protein kinase ,VASP, vasodilator-stimulated phosphoprotein - Abstract
Visual Abstract, Highlights • In patients with STEMI treated with primary percutaneous coronary intervention, iron deficiency is associated with larger infarcts, more extensive microvascular obstruction, and a higher frequency of adverse left ventricular remodeling. • An iron-deficient diet reduces the tolerance to ischemia/reperfusion in mice at least in part by interfering with the cardioprotective pathway eNOS/soluble guanylate cyclase/protein kinase G. • An iron-deficient diet reduces eNOS activity by increasing oxidative/nitrosative stress and its proteasome-dependent degradation. • Not only iron excess but also iron deficiency may have deleterious effects in the context of acute myocardial ischemia., Summary In patients with a first anterior ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention, iron deficiency (ID) was associated with larger infarcts, more extensive microvascular obstruction, and higher frequency of adverse left ventricular remodeling as assessed by cardiac magnetic resonance imaging. In mice, an ID diet reduced the activity of the endothelial nitric oxide synthase/soluble guanylate cyclase/protein kinase G pathway in association with oxidative/nitrosative stress and increased infarct size after transient coronary occlusion. Iron supplementation or administration of an sGC activator before ischemia prevented the effects of the ID diet in mice. Not only iron excess, but also ID, may have deleterious effects in the setting of ischemia and reperfusion.
- Published
- 2021
43. Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion
- Author
-
David Garcia-Dorado, Federico Mayor, Javier Inserte, Antonio Rodríguez-Sinovas, Petronila Penela, Paula Ramos, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (España), European Commission, Comunidad de Madrid, Fundación Ramón Areces, UAM. Departamento de Biología Molecular, [Penela P, Mayor Jr F] Departamento de Biología Molecular, Centro de Biología Molecular 'Severo Ochoa' (UAM-CSIC), Madrid, Spain. Instituto de Investigación Sanitaria La Princesa, Madrid, Spain. CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Inserte J, Rodriguez-Sinovas A, Garcia-Dorado D] CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Ramos P] Departamento de Biología Molecular, Centro de Biología Molecular 'Severo Ochoa' (UAM-CSIC), Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Male ,0301 basic medicine ,Research paper ,G-Protein-Coupled Receptor Kinase 2 ,Swine ,Myocardial Ischemia ,Cardioprotection ,Pharmacology ,enfermedades cardiovasculares::enfermedades cardíacas::enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::enfermedades cardiovasculares::enfermedades cardiovasculares::daño por reperfusión miocárdica [ENFERMEDADES] ,RISK, reperfusion injury salvage kinase pathway ,HF, heart failure ,aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intracelular::cinasas de receptores acoplados a proteína G::cinasas de receptores adrenérgicos beta::aminoácidos, péptidos y proteínas::cinasa 2 del receptor acoplado a proteína G [COMPUESTOS QUÍMICOS Y DROGAS] ,0302 clinical medicine ,Cardiovascular Diseases::Heart Diseases::Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Cardiovascular Diseases::Cardiovascular Diseases::Myocardial Reperfusion Injury [DISEASES] ,Phosphorylation ,Cells, Cultured ,Amino Acids, Peptides, and Proteins::Amino Acids, Peptides, and Proteins::Proteins::Intracellular Signaling Peptides and Proteins::G-Protein-Coupled Receptor Kinases::beta-Adrenergic Receptor Kinases::G-Protein-Coupled Receptor Kinase 2 [CHEMICALS AND DRUGS] ,biology ,Ischemia-reperfusion ,Calpain ,General Medicine ,Reperfusió miocardíaca ,Biología y Biomedicina / Biología ,metabolismo ,030220 oncology & carcinogenesis ,Proteïna quinasa CK2 ,MI, myocardial infarction ,Signal transduction ,Oxidation-Reduction ,Proteasome Endopeptidase Complex ,Ischemia ,Calpains ,GRK2, G-protein coupled receptor kinase 2 ,GRK2 ,Myocardial Reperfusion Injury ,Models, Biological ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Pin1 ,medicine ,Animals ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Adaptor Proteins, Signal Transducing ,Proteasome ,business.industry ,Beta adrenergic receptor kinase ,AKT ,metabolism ,medicine.disease ,Rats ,Disease Models, Animal ,030104 developmental biology ,GPCR, G-protein coupled receptor ,Proteolysis ,biology.protein ,I/R, Ischemia/Reperfusion ,Models animals en la investigació ,Investigative Techniques::Models, Animal::Investigative Techniques::Disease Models, Animal [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,técnicas de investigación::modelos animales::técnicas de investigación::modelos de enfermedad en animales [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,business ,Proto-Oncogene Proteins c-akt ,Biomarkers - Abstract
Background: Identification of signaling pathways altered at early stages after cardiac ischemia/reperfusion (I/R) is crucial to develop timely therapies aimed at reducing I/R injury. The expression of G protein-coupled receptor kinase 2 (GRK2), a key signaling hub, is up-regulated in the long-term in patients and in experimental models of heart failure. However, whether GRK2 levels change at early time points following myocardial I/R and its functional impact during this period remain to be established. Methods: We have investigated the temporal changes of GRK2 expression and their potential relationships with the cardioprotective AKT pathway in isolated rat hearts and porcine preclinical models of I/R. Findings: Contrary to the maladaptive up-regulation of GRK2 reported at later times after myocardial infarction, successive GRK2 phosphorylation at specific sites during ischemia and early reperfusion elicits GRK2 degradation by the proteasome and calpains, respectively, thus keeping GRK2 levels low during early I/R in rat hearts. Concurrently, I/R promotes decay of the prolyl-isomerase Pin1, a positive regulator of AKT stability, and a marked loss of total AKT protein, resulting in an overall decreased activity of this pro-survival pathway. A similar pattern of concomitant down-modulation of GRK2/AKT/Pin1 protein levels in early I/R was observed in pig hearts. Calpain and proteasome inhibition prevents GRK2/Pin1/AKT degradation, restores bulk AKT pathway activity and attenuates myocardial I/R injury in isolated rat hearts. Interpretation: Preventing transient degradation of GRK2 and AKT during early I/R might improve the potential of endogenous cardioprotection mechanisms and of conditioning strategies., Instituto de Salud Carlos III, Spain (grant PI-16/00232; RETICS-RIC-RD12/0042/0021 to DGD, cofunded with European Regional Development Fund-FEDER contribution, and grants PI14-00435 and PI17-00576 to PP), by Ministerio de Economía; Industria y Competitividad (MINECO) of Spain (grant SAF2017-84125-R to F.M.); by CIBERCV-Instituto de Salud Carlos III, Spain (grant CB16/11/00479 to DGD and CB16/11/00278 to F.M, cofunded with European Regional Development Fund-FEDER contribution), and Programa de Actividades en Biomedicina de la Comunidad de Madrid-B2017/BMD-3671-INFLAMUNE to F.M. We also acknowledge institutional support to the CBMSO from Fundación Ramón Areces
- Published
- 2019
44. Efficacy of a cysteine protease inhibitor compared with enalapril in murine heart failure models.
- Author
-
Aluja D, Delgado-Tomás S, Barrabés JA, Miró-Casas E, Ruiz-Meana M, Rodríguez-Sinovas A, Benito B, Wang J, Song LS, Ferreira-González I, and Inserte J
- Abstract
Cysteine proteases calpains contribute to heart failure (HF), but it remains unknown whether their inhibition provides any benefit compared to standard pharmacological treatment for HF. Here, we characterize the pharmacological properties of NPO-2270 (NPO) as a potent inhibitor of cysteine proteases. Then, we describe that acute administration of NPO in rodent models of transient ischemia at the time of reperfusion reduces myocardial infarction, while its chronic oral administration attenuates adverse remodeling and cardiac dysfunction induced by ischemic and non-ischemic pathological stimuli more effectively than enalapril when given at the same dose. Finally, we provide evidence showing that the effects of NPO correlate with calpain inhibition and the preservation of the T-tubule morphology, due at least in part to reduced cleavage of the calpain substrate junctophilin-2. Together, our data highlight the potential of cysteine protease inhibition with NPO as a therapeutic strategy for the treatment of heart failure., Competing Interests: Dr. J. Inserte received a grant from Landsteiner Genmed SL., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
45. Connexin 43 modulates reverse electron transfer in cardiac mitochondria from inducible knock-out Cx43 Cre-ER(T)/fl mice by altering the coenzyme Q pool.
- Author
-
Consegal M, Miró-Casas E, Barba I, Ruiz-Meana M, Inserte J, Benito B, Rodríguez C, Ganse FG, Rubio-Unguetti L, Llorens-Cebrià C, Ferreira-González I, and Rodríguez-Sinovas A
- Subjects
- Animals, Mice, Electron Transport drug effects, Membrane Potential, Mitochondrial drug effects, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury pathology, Myocardial Reperfusion Injury genetics, Male, Ubiquinone analogs & derivatives, Ubiquinone pharmacology, Ubiquinone metabolism, Ubiquinone deficiency, Mitochondria, Heart metabolism, Mitochondria, Heart pathology, Mitochondria, Heart drug effects, Connexin 43 metabolism, Connexin 43 genetics, Mice, Knockout, Reactive Oxygen Species metabolism
- Abstract
Succinate accumulates during myocardial ischemia and is rapidly oxidized during reperfusion, leading to reactive oxygen species (ROS) production through reverse electron transfer (RET) from mitochondrial complex II to complex I, and favoring cell death. Given that connexin 43 (Cx43) modulates mitochondrial ROS production, we investigated whether Cx43 influences RET using inducible knock-out Cx43
Cre-ER(T)/fl mice. Oxygen consumption, ROS production, membrane potential and coenzyme Q (CoQ) pool were analyzed in subsarcolemmal (SSM, expressing Cx43) and interfibrillar (IFM) cardiac mitochondria isolated from wild-type Cx43fl/fl mice and Cx43Cre-ER(T)/fl knock-out animals treated with 4-hydroxytamoxifen (4OHT). In addition, infarct size was assessed in isolated hearts from these animals submitted to ischemia-reperfusion (IR), and treated or not with malonate, a complex II inhibitor attenuating RET. Succinate-dependent ROS production and RET were significantly lower in SSM, but not IFM, from Cx43-deficient animals. Mitochondrial membrane potential, a RET driver, was similar between groups, whereas CoQ pool (2.165 ± 0.338 vs. 4.18 ± 0.55 nmol/mg protein, p < 0.05) and its reduction state were significantly lower in Cx43-deficient animals. Isolated hearts from Cx43Cre-ER(T)/fl mice treated with 4OHT had a smaller infarct size after IR compared to Cx43fl/fl , despite similar concentration of succinate at the end of ischemia, and no additional protection by malonate. Cx43 deficiency attenuates ROS production by RET in SSM, but not IFM, and was associated with a decrease in CoQ levels and a change in its redox state. These results may partially explain the reduced infarct size observed in these animals and their lack of protection by malonate., (© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2024
- Full Text
- View/download PDF
46. Long-Term Protective Effects of Succinate Dehydrogenase Inhibition during Reperfusion with Malonate on Post-Infarction Left Ventricular Scar and Remodeling in Mice.
- Author
-
Valls-Lacalle L, Consegal M, Ganse FG, Yáñez-Bisbe L, Pastor J, Ruiz-Meana M, Inserte J, Benito B, Ferreira-González I, and Rodríguez-Sinovas A
- Subjects
- Animals, Mice, Male, Cicatrix pathology, Cicatrix drug therapy, Mice, Inbred C57BL, Malonates pharmacology, Myocardial Infarction drug therapy, Myocardial Infarction pathology, Succinate Dehydrogenase metabolism, Succinate Dehydrogenase antagonists & inhibitors, Ventricular Remodeling drug effects, Myocardial Reperfusion Injury drug therapy, Myocardial Reperfusion Injury pathology
- Abstract
Succinate dehydrogenase inhibition with malonate during initial reperfusion reduces myocardial infarct size in both isolated mouse hearts subjected to global ischemia and in in situ pig hearts subjected to transient coronary ligature. However, the long-term effects of acute malonate treatment are unknown. Here, we investigated whether the protective effects of succinate dehydrogenase inhibition extend to a reduction in scar size and adverse left ventricular remodeling 28 days after myocardial infarction. Initially, ten wild-type mice were subjected to 45 min of left anterior descending coronary artery (LAD) occlusion, followed by 24 h of reperfusion, and were infused during the first 15 min of reperfusion with saline with or without disodium malonate (10 mg/kg/min, 120 μL/kg/min). Malonate-treated mice depicted a significant reduction in infarct size (15.47 ± 3.40% of area at risk vs. 29.34 ± 4.44% in control animals, p < 0.05), assessed using triphenyltetrazolium chloride. Additional animals were then subjected to a 45 min LAD ligature, followed by 28 days of reperfusion. Treatment with a single dose of malonate during the first 15 min of reperfusion induced a significant reduction in scar area, measured using Picrosirius Red staining (11.94 ± 1.70% of left ventricular area (n = 5) vs. 23.25 ± 2.67% (n = 9), p < 0.05), an effect associated with improved ejection fraction 28 days after infarction, as determined using echocardiography, and an attenuated enhancement in expression of the pro-inflammatory and fibrotic markers NF-κB and Smad2/3 in remote myocardium. In conclusion, a reversible inhibition of succinate dehydrogenase with a single dose of malonate at the onset of reperfusion has long-term protective effects in mice subjected to transient coronary occlusion., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
47. TRPV4 Channels Promote Pathological, but Not Physiological, Cardiac Remodeling through the Activation of Calcineurin/NFAT and TRPC6.
- Author
-
Yáñez-Bisbe L, Moya M, Rodríguez-Sinovas A, Ruiz-Meana M, Inserte J, Tajes M, Batlle M, Guasch E, Mas-Stachurska A, Miró E, Rivas N, Ferreira González I, Garcia-Elias A, and Benito B
- Subjects
- Animals, Mice, Cells, Cultured, Fibrosis, Isoproterenol, Mice, Transgenic, Myocytes, Cardiac metabolism, NFATC Transcription Factors genetics, NFATC Transcription Factors metabolism, TRPC6 Cation Channel genetics, TRPC6 Cation Channel metabolism, Calcineurin metabolism, Heart Failure metabolism, TRPV Cation Channels genetics, TRPV Cation Channels metabolism, Ventricular Remodeling genetics
- Abstract
TRPV4 channels, which respond to mechanical activation by permeating Ca
2+ into the cell, may play a pivotal role in cardiac remodeling during cardiac overload. Our study aimed to investigate TRPV4 involvement in pathological and physiological remodeling through Ca2+ -dependent signaling. TRPV4 expression was assessed in heart failure (HF) models, induced by isoproterenol infusion or transverse aortic constriction, and in exercise-induced adaptive remodeling models. The impact of genetic TRPV4 inhibition on HF was studied by echocardiography, histology, gene and protein analysis, arrhythmia inducibility, Ca2+ dynamics, calcineurin (CN) activity, and NFAT nuclear translocation. TRPV4 expression exclusively increased in HF models, strongly correlating with fibrosis. Isoproterenol-administered transgenic TRPV4-/- mice did not exhibit HF features. Cardiac fibroblasts (CFb) from TRPV4+/+ animals, compared to TRPV4-/-, displayed significant TRPV4 overexpression, elevated Ca2+ influx, and enhanced CN/NFATc3 pathway activation. TRPC6 expression paralleled that of TRPV4 in all models, with no increase in TRPV4-/- mice. In cultured CFb, the activation of TRPV4 by GSK1016790A increased TRPC6 expression, which led to enhanced CN/NFATc3 activation through synergistic action of both channels. In conclusion, TRPV4 channels contribute to pathological remodeling by promoting fibrosis and inducing TRPC6 upregulation through the activation of Ca2+ -dependent CN/NFATc3 signaling. These results pose TRPV4 as a primary mediator of the pathological response.- Published
- 2024
- Full Text
- View/download PDF
48. Cardiac fibroblasts display endurance to ischemia, high ROS control and elevated respiration regulated by the JAK2/STAT pathway.
- Author
-
Beà A, Valero JG, Irazoki A, Lana C, López-Lluch G, Portero-Otín M, Pérez-Galán P, Inserte J, Ruiz-Meana M, Zorzano A, Llovera M, and Sanchis D
- Subjects
- Animals, Fibroblasts metabolism, Ischemia, Proto-Oncogene Proteins c-bcl-2 metabolism, Rats, Reactive Oxygen Species metabolism, Respiration, STAT3 Transcription Factor genetics, STAT3 Transcription Factor metabolism, Signal Transduction, Antioxidants, Janus Kinase 2 genetics, Janus Kinase 2 metabolism
- Abstract
Cardiovascular diseases are the leading cause of death globally and more than four out of five cases are due to ischemic events. Cardiac fibroblasts (CF) contribute to normal heart development and function, and produce the post-ischemic scar. Here, we characterize the biochemical and functional aspects related to CF endurance to ischemia-like conditions. Expression data mining showed that cultured human CF (HCF) express more BCL2 than pulmonary and dermal fibroblasts. In addition, gene set enrichment analysis showed overrepresentation of genes involved in the response to hypoxia and oxidative stress, respiration and Janus kinase (JAK)/Signal transducer and Activator of Transcription (STAT) signaling pathways in HCF. BCL2 sustained survival and proliferation of cultured rat CF, which also had higher respiration capacity and reactive oxygen species (ROS) production than pulmonary and dermal fibroblasts. This was associated with higher expression of the electron transport chain (ETC) and antioxidant enzymes. CF had high phosphorylation of JAK2 and its effectors STAT3 and STAT5, and their inhibition reduced viability and respiration, impaired ROS control and reduced the expression of BCL2, ETC complexes and antioxidant enzymes. Together, our results identify molecular and biochemical mechanisms conferring survival advantage to experimental ischemia in CF and show their control by the JAK2/STAT signaling pathway. The presented data point to potential targets for the regulation of cardiac fibrosis and also open the possibility of a general mechanism by which somatic cells required to acutely respond to ischemia are constitutively adapted to survive it., (© 2021 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
- Published
- 2022
- Full Text
- View/download PDF
49. Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy.
- Author
-
Aluja D, Delgado-Tomás S, Ruiz-Meana M, Barrabés JA, and Inserte J
- Subjects
- Animals, Calcium-Binding Proteins, Cardiomegaly drug therapy, Calpain metabolism, Heart Failure drug therapy
- Abstract
Despite advances in its treatment, heart failure remains a major cause of morbidity and mortality, evidencing an urgent need for novel mechanism-based targets and strategies. Myocardial hypertrophy, caused by a wide variety of chronic stress stimuli, represents an independent risk factor for the development of heart failure, and its prevention constitutes a clinical objective. Recent studies performed in preclinical animal models support the contribution of the Ca
2+ -dependent cysteine proteases calpains in regulating the hypertrophic process and highlight the feasibility of their long-term inhibition as a pharmacological strategy. In this review, we discuss the existing evidence implicating calpains in the development of cardiac hypertrophy, as well as the latest advances in unraveling the underlying mechanisms. Finally, we provide an updated overview of calpain inhibitors that have been explored in preclinical models of cardiac hypertrophy and the progress made in developing new compounds that may serve for testing the efficacy of calpain inhibition in the treatment of pathological cardiac hypertrophy.- Published
- 2022
- Full Text
- View/download PDF
50. Aging Impairs Reverse Remodeling and Recovery of Ventricular Function after Isoproterenol-Induced Cardiomyopathy.
- Author
-
Yáñez-Bisbe L, Garcia-Elias A, Tajes M, Almendros I, Rodríguez-Sinovas A, Inserte J, Ruiz-Meana M, Farré R, Farré N, and Benito B
- Subjects
- Animals, Cardiomyopathies, Collagen genetics, Female, Gene Expression Regulation, Heart Failure physiopathology, Mice, Mice, Inbred C57BL, Stroke Volume, Ventricular Function, Left, Ventricular Remodeling, Aging, Disease Models, Animal, Fibrosis, Heart Failure chemically induced, Isoproterenol toxicity
- Abstract
Information about heart failure with reduced ejection fraction (HFrEF) in women and the potential effects of aging in the female heart is scarce. We investigated the vulnerability to develop HFrEF in female elderly mice compared to young animals, as well as potential differences in reverse remodeling. First, HF was induced by isoproterenol infusion (30 mg/kg/day, 28 days) in young (10-week-old) and elderly (22-month-old) female mice. In a second set of animals, mice underwent isoproterenol infusion followed by no treatment during 28 additional days. Cardiac remodeling was assessed by echocardiography, histology and gene expression of collagen-I and collagen-III. Following isoproterenol infusion, elderly mice developed similar HFrEF features compared to young animals, except for greater cell hypertrophy and tissue fibrosis. After beta-adrenergic withdrawal, young female mice experienced complete reversal of the HFrEF phenotype. Conversely, reversed remodeling was impaired in elderly animals, with no significant recovery of LV ejection fraction, cardiomyocyte hypertrophy and collagen deposition. In conclusion, chronic isoproterenol infusion is a valid HF model for elderly and young female mice and induces a similar HF phenotype in both. Elderly animals, unlike young, show impaired reverse remodeling, with persistent tissue fibrosis and cardiac dysfunction even after beta-adrenergic withdrawal.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.